Purpose <p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that often leads to dementia, cognitive impairment and neuroinflammation. Studies have demonstrated the neuroprotective effects of GLP-1 receptor agonists in rodent models by enhancing cognition, reducing oxidative stress and mitigating AD pathology. This study aims to investigate the cognitive-enhancing, anxiolytic and neuroprotective effects of Liraglutide in scopolamine-induced zebrafish model of Alzheimer’s disease.</p> Methods <p>This preventive study design includes treatment of Zebrafish with liraglutide (100 µg/kg or 200 µg/kg), donepezil, or imipramine following scopolamine-induced cognitive impairment. Behavioral assessments included the Novel Tank Test (NTT) to measure anxiety-related responses and the T-maze test to evaluate memory function. Biochemical analyses were conducted to assess neuroprotective effects, including antioxidant enzyme activity, lipid peroxidation and acetylcholinesterase (AChE) levels.</p> Results <p>Liraglutide demonstrated anxiolytic-like effect with the 200&#xa0;µg/kg dose significantly improving exploratory behavior compared to the lower dose. Donepezil demonstrated superior cognitive benefits, while imipramine induced sedative effects. In the T-maze test, liraglutide at 200&#xa0;µg/kg significantly reversed scopolamine-induced memory deficits and decreased locomotion. Neuroprotective benefits were confirmed by increased antioxidant enzyme activity and reduced lipid peroxidation.</p> Conclusion <p>Liraglutide significantly reduced cognitive impairment and exhibited neuroprotective effects in a zebrafish model of Alzheimer’s disease. These findings support preclinical evidence for potential therapeutic relevance in Alzheimer’s treatment and reinforce the utility of zebrafish as a translational model for neurodegenerative research.</p>